Celldex Therapeutics Is A Clinical Stage Biotechnology Company Based In Hamptonnew Jerseyfounded In 2004It Focuses On Developing Antibody Based Therapeutics For Severe Inflammatoryallergicautoimmuneand Other Diseasesthe Company Specializes In Monoclonal And Bispecific Antibodies That Modulate Immune Responsesaiming To Address Unmet Medical Needs In Chronic And Life Threatening Conditions Celldex S Clinical Pipeline Includes Barzolvolimaba Monoclonal Antibody Currently In Phase 2 Trials For Chronic Spontaneous Urticaria And Other Mast Cell Mediated Disordersthe Company Also Develops Bispecific Antibodies Designed To Target Multiple Disease Pathwayscelldex Collaborates With Academic Institutions And Industry Leaders To Advance Its Research And Therapeutic Developmentkey Milestones Include The Acquisition Of Avant Immunotherapeutics In 2006 And The Initiation Of Phase 2 Trials For Barzolvolimab In 2020Reflecting Its Commitment To Innovation In Immune Mediated Diseases
